tiprankstipranks
Trending News
More News >

Shanghai Henlius Biotech’s HLX22 Receives Orphan-Drug Designation from European Commission

Story Highlights
  • Shanghai Henlius Biotech focuses on developing HER2-targeting therapies for cancer treatment.
  • HLX22 received orphan-drug designation for gastric cancer, highlighting its market potential.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Shanghai Henlius Biotech’s HLX22 Receives Orphan-Drug Designation from European Commission

Confident Investing Starts Here:

An update from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.

Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative monoclonal antibody products. The company is known for its work on HER2-targeting therapies, with a market focus on treating various cancers, including gastric and breast cancer.

Average Trading Volume: 1,523,245

Technical Sentiment Signal: Buy

Current Market Cap: HK$22.88B

For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1